Article Synopsis
- Black women have higher rates of taxane-induced peripheral neuropathy (TIPN) when undergoing treatment with paclitaxel, leading to more dose reductions and higher recurrence rates in breast cancer cases compared to White women.
- The EAZ171 study aimed to validate genetic predictors of TIPN and compare the incidence of TIPN along with dose adjustments between Black women receiving paclitaxel (once weekly) and docetaxel (every three weeks).
- Results showed that high-risk genotypes did not significantly differ in TIPN occurrences, but those receiving the weekly paclitaxel experienced a higher rate of TIPN and required more dose reductions compared to those on docetaxel.
Video Abstracts
Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Black women experience higher rates of taxane-induced peripheral neuropathy (TIPN) compared with White women when receiving adjuvant once weekly paclitaxel for early-stage breast cancer, leading to more dose reductions and higher recurrence rates. EAZ171 aimed to prospectively validate germline predictors of TIPN and compare rates of TIPN and dose reductions in Black women receiving (neo)adjuvant once weekly paclitaxel and once every 3 weeks docetaxel for early-stage breast cancer.
Methods: Women with early-stage breast cancer who self-identified as Black and had intended to receive (neo)adjuvant once weekly paclitaxel or once every 3 weeks docetaxel were eligible, with planned accrual to 120 patients in each arm. Genotyping was performed to determine germline neuropathy risk. Grade 2-4 TIPN by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 was compared between high- versus low-risk genotypes and between once weekly paclitaxel versus once every 3 weeks docetaxel within 1 year. Patient-rated TIPN and patient-reported outcomes were compared using patient-reported outcome (PRO)-CTCAE and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity.
Results: Two hundred and forty of 249 enrolled patients had genotype data, and 91 of 117 (77.8%) receiving once weekly paclitaxel and 87 of 118 (73.7%) receiving once every 3 weeks docetaxel were classified as high-risk. Physician-reported grade 2-4 TIPN was not significantly different in high- versus low-risk genotype groups with once weekly paclitaxel (47% 35%; = .27) or with once every 3 weeks docetaxel (28% 19%; = .47). Grade 2-4 TIPN was significantly higher in the once weekly paclitaxel versus once every 3 weeks docetaxel arm by both physician-rated CTCAE (45% 29%; = .02) and PRO-CTCAE (40% 24%; = .03). Patients receiving once weekly paclitaxel required more dose reductions because of TIPN (28% 9%; < .001) or any cause (39% 25%; = .02).
Conclusion: Germline variation did not predict risk of TIPN in Black women receiving (neo)adjuvant once weekly paclitaxel or once every 3 weeks docetaxel. Once weekly paclitaxel was associated with significantly more grade 2-4 TIPN and required more dose reductions than once every 3 weeks docetaxel.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670807 | PMC |
| http://dx.doi.org/10.1200/JCO.24.00526 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Leptomeningeal Carcinomatosis and Myelophthisic Anemia as Initial Manifestations of Metastatic Lobular Breast Cancer.
Case Rep Oncol Med
August 2025
Department of Internal Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, USA.
Breast cancer can spread to the brain and bone, usually presenting as parenchymal and osteoblastic lesions, respectively. We present a unique case of a 59-year-old woman undergoing treatment for invasive lobular breast cancer who presented with nausea, vomiting, headache, and generalized weakness. Her clinical presentation and subsequent evaluation led to a discovery of leptomeningeal carcinomatosis and myelophthisic anemia presenting simultaneously as her initial metastases.
View Article and Find Full Text PDFSuppression of Paclitaxel-Induced Neuropathy and Ovarian Tumor Growth by Mn Porphyrin, MnTnBuOE-2-PyP (BMX-001).
Oxid Med Cell Longev
September 2025
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke University School of Medicine, Durham 27710, North Carolina, USA.
Numerous cellular and animal studies demonstrated the ability of redox-active Mn(III) -alkyl- and -alkoxyalkylpyridyporphyrins (MnPs) to protect normal tissue while suppressing tumor growth. The mechanism primarily involves the modulation of NF-кB and Nrf2 signaling pathways via catalysis of MnP/HO-driven protein thiol oxidation. Such differential protection/suppression effects have paved the way of Mn porphyrins (commonly known as mimics of superoxide dismutase) into clinical trials, therefore introducing new line of therapeutics that are affecting cellular redox status/oxidative stress, rather than specific proteins.
View Article and Find Full Text PDFSuccessful Treatment of an Advanced Larynx Carcinoma Using Neo-Adjuvant Chemo-Immunotherapy and Cisplatin/Radiotherapy for a Patient with Rendu-Osler Disease.
J Clin Med
August 2025
Department of Oncology-Hematology, Centre Hospitalier de Saint-Quentin, 1 Av. Michel de l'Hospital BP 608, 02321 Saint-Quentin, France.
: Rendu-Osler disease is a rare genetic disease, characterized by widespread telangiectasia that can involve the skin and mucous membranes. The diagnosis is based on spontaneous and recurrent epistaxis; various mucosal and cutaneous telangiectasia at typical sites; visceral manifestations including gastrointestinal telangiectasia or pulmonary, cerebral, or hepatic arteriovenous malformation; and a first-degree relative with hereditary hemorrhagic telangiectasia. Squamous cell carcinoma of the larynx generally develops in patients with a smoking history.
View Article and Find Full Text PDFPaclitaxel-induced Peripheral Neuropathy and Quality of Life: Sub-analysis of the MICHEL Study.
Anticancer Res
September 2025
Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, Ibaraki, Japan;
Background/aim: Paclitaxel, a taxane-class drug commonly used as part of a chemotherapy regimen for breast cancer, is causative for chemotherapy-induced peripheral neuropathy (CIPN). The MICHEL study was conducted to evaluate the efficacy of mirogabalin against CIPN which included, among its secondary endpoints, a questionnaire in which patients rated in detail the impact of their CIPN on their activities of daily living. In this study, we performed a sub-analysis for this secondary endpoint and attempted to identify acute changes that signaled CIPN.
View Article and Find Full Text PDFProspective Phase II Trial of Definitive Chemoradiation and Concurrent Nivolumab in Locally Advanced p16+ Oropharynx Cancer.
Adv Radiat Oncol
October 2025
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Purpose: We conducted a prospective, single-institution phase II trial to test the hypothesis that the addition of nivolumab to definitive chemoradiation would improve the progression-free survival (PFS) among patients with high-risk p16+ oropharyngeal squamous cell carcinoma (OPSCC).
Methods And Materials: Patients with previously-untreated locoregionally advanced, p16+ OPSCC (clinical T4/N3, matted lymph nodes, and/or retropharyngeal lymphadenopathy) were enrolled. Patients received a priming dose of nivolumab, concurrent nivolumab and chemoradiation (70 Gy to PTVhigh, 56 Gy to PTVlow, weekly carboplatin/paclitaxel), and 4 cycles of adjuvant nivolumab over 12 weeks.